I am certain you can put a line through DEP Doc. It’s going to...

I am certain you can put a line through DEP Doc. It’s going to be mothballed IMO. Results were weak.

DEP Iri and DEP Cab are looking increasingly unlikely to be licenced, and Starpharma do not have the expertise or funds to conduct a Phase 3 trial.

Viraleze trial failed to achieve its overall primary endpoint. Interesting and promising cherry picked subset data but unlikely to change the trajectory of pathetic world wide sales.

Condoms are irrelevant.

The only saviour I can see is AstraZeneca. Otherwise the share price is likely to just meander lower and lower over time as salaries and administration eat into the cash balance.

Removal from the All Ords is almost a certainty in March eliminating any hint of relevance as an ASX company. Crushing end of financial year tax loss selling to begin in June.

All the above is IMHO.